Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc.
Your view on FNCHQ
Overview
What the company does, where it operates, and who runs it.
About Finch Therapeutics Group, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Matthew Blischak
- Headquarters
- 75 State Street, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Matthew Blischak
- Headquarters
- 75 State Street, Boston, MA, US
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.
The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Finch Therapeutics Group, Inc., and the rating behind it. FNCHQ last traded at $10.10; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Finch Therapeutics Group, Inc.. Starting points for Finch Therapeutics Group, Inc.: EPS -$8.64, beta 0.98 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Finch Therapeutics Group, Inc.. Finch Therapeutics Group, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Finch Therapeutics Group, Inc.. Trailing twelve-month EPS for Finch Therapeutics Group, Inc. stands at -$8.64. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Finch Therapeutics Group, Inc.. Finch Therapeutics Group, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Finch Therapeutics Group, Inc. valued side by side against its closest peers. Finch Therapeutics Group, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Finch Therapeutics Group, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Finch Therapeutics Group, Inc. executives and directors. Shares of Finch Therapeutics Group, Inc. have traded between $2.00 and $16.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Finch Therapeutics Group, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Finch Therapeutics Group, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Finch Therapeutics Group, Inc.. Coverage tracks Finch Therapeutics Group, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.